3-dimensional large capacity cell encapsulation device assembly

Patent metadata

Field	Value
Publication number	US-12296125-B2
Application number	US-202117387855-A
Country	US
Kind code	B2
Filing date	Jul 28, 2021
Priority date	Mar 7, 2013
Publication date	May 13, 2025
Grant date	May 13, 2025

Abstract

Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.

First claim

What is claimed is:

1. A cell encapsulation assembly, said assembly comprising a length, a width, first and second opposing long sides extending lengthwise of the assembly, and first and second opposing short sides extending widthwise of the assembly, wherein the assembly has a longest axis extending lengthwise of the assembly, the assembly further comprising at least two planar cell chambers and a cell-free region along the longest axis separating adjacent planar cell chambers, wherein each chamber is fluidly separated from another chamber, and each chamber comprises a semi-permeable membrane comprising an inner surface configured to be in contact with cells that are placed in the respective chamber, wherein each chamber has at least one loading port extending from outside of the chamber to inside of the chamber, wherein each chamber is configured to be sealed to contain the cells that are placed in the respective chamber, and at least a portion of an outer surface of the cell encapsulating assembly is configured to be placed in direct contact with host tissue upon implantation of the cell encapsulating assembly into a mammalian host, wherein the assembly comprises at least one suture tab at the first short side of the assembly for securing the assembly at an implantation site inside the host, wherein each loading port extends from outside of the respective chamber to inside of the respective chamber at the second short side of the assembly, and wherein the cell-free region is bent.

2. The assembly of claim 1 , further comprising cells contained within the cell chambers.

3. The assembly of claim 2 , wherein the cells are human definitive endoderm-lineage cells, human pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells, human endocrine precursor cells, or human immature beta cells.

4. The assembly of claim 1 , wherein each chamber has at least two loading ports extending from outside of the chamber to inside of the chamber.

5. The assembly of claim 1 , wherein the assembly comprises a first layer of semipermeable material and a second layer of semipermeable material forming the cell chambers therebetween, wherein the first and second layers are secured to each other at locations between the cell chambers to form the cell free region.

6. The assembly of claim 5 , wherein the cell-free region comprises a welded region bonding the first and second layers to each other.

7. The assembly of claim 6 , wherein the welded region extends between and intersects the first and second short sides of the assembly.

8. The assembly of claim 1 , wherein the tab extends lengthwise of the assembly from the first short side.

9. The assembly of claim 8 , wherein the tab has a rounded peripheral edge.

10. The assembly of claim 1 , wherein the tab comprises two suture tabs at the first short side of the assembly, wherein the two tabs are spaced apart from each other widthwise of the assembly.

11. The assembly of claim 10 , each tab extends from an intersection of an end of the first short side and an adjacent end of one of the long sides.

12. The assembly of claim 10 , wherein the tabs extend lengthwise of the assembly from the first short side.

13. The assembly of claim 1 , wherein an angle between the cell chambers is less than 175 degrees.

Assignees

• Viacyte Inc

Inventors

• So Vincent
• Martinson Laura
• Green Chad
• Scott Michael
• Zamarripa Mario

Classifications

• A61M2202/09

  Body tissue · CPC title

• A61M2205/04

  implanted · CPC title

• A61F2/022 Primary

  Artificial gland structures using bioreactors (hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36) · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61M31/002 Primary

  Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50) · CPC title